Rune Labs, a San Francisco, CA-based precision neurology software and data company, raised $12M in a strategic funding.
The round, which brought the total amount to $42M, was led by Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures and TruVenturo GmbH. Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures and former President of Medical Devices at Verily, will join Rune Labs’ board of directors.
The company intends to use the funds to accelerate the adoption of novel parkinson’s technologies.
Led by CEO Brian Pepin, Rune Labs is a software and data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is its care delivery ecosystem for Parkinson’s disease, enabling patients and clinicians to better manage Parkinson’s by providing access to curated dashboards summarizing a range of patient data sources, and by connecting patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune’s technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs.
Commenting on the news, Brian Pepin said: “With over 25 years of experience, Jordi brings deep knowledge in building businesses and products and the intersection of data and healthcare. This strategic partnership with Nexus NeuroTech Ventures is in line with our use of modern AI tools to support patients, clinicians, and our pharma partners, and speaks to our ambition to have a deep impact in the way Parkinson’s is understood and treated.”
FinSMEs
12/01/2024